Every day, roughly 1,300 people acquire HIV. Prevention drugs have existed for a decade. The problem is logistics, not science. Merck thinks a once-monthly pill can solve it — and researchers say it could be manufactured for under $5 per person per year.
image from Gemini Imagen 4
Merck's investigational once-monthly oral HIV prevention pill MK-8527 could be manufactured for approximately $5 per person annually, a fraction of Gilead's twice-yearly injectable lenacapavir's $28,218 US list price, sparking debate over pricing strategy before Phase 3 results arrive in 2027. Over 170 advocacy groups have urged Merck to commit to a global access plan at or below $40 per person per year in low- and middle-income countries before regulatory approval, citing lessons from lenacapavir's delayed affordability. With only 18% of global PrEP need currently met, the drug's simplified monthly oral dosing could address adherence barriers that have limited uptake of daily regimens.
Merck's experimental HIV prevention pill could be manufactured for $5 per person a year. That number is not in the published scientific literature — it comes from a cost analysis cited by STAT News — but it is already shaping the conversation around MK-8527 before the Phase 3 results are even in.
The drug is a once-monthly oral pill, a nucleoside reverse transcriptase translocation inhibitor, now in two late-stage trials enrolling nearly 9,000 participants across 16 countries (PrEPWatch). The Phase 2 data, presented at the International AIDS Society conference in Kigali in July 2025, showed it was safe, well-tolerated, and capable of protecting against infection within 24 hours of a dose (Merck press release). Merck is collaborating with the Gates Foundation on the trials, which are running through 2027.
What makes the $5 figure consequential is what it implies about the gap between production cost and eventual price. Gilead Sciences' twice-yearly injectable lenacapavir — currently the most durable PrEP option on the market — carries a US list price of $28,218 per person per year. Researchers writing in The Lancet HIV estimated generic lenacapavir could be produced for $35 to $46 per person per year (UNAIDS). At $5, MK-8527 sits well below both numbers, and advocates are watching to see whether Merck prices it closer to production cost or closer to the Gilead precedent.
More than 170 patient advocacy groups from 30 countries sent a letter to Merck CEO Robert Davis in February urging the company to commit to a global access strategy before regulatory approval, not after (Health GAP letter). The letter asked Merck to price MK-8527 at or near parity with generic oral PrEP in low- and middle-income countries from the point of introduction — and to make that price public. The target the groups named: less than $40 per person per year, enough to enable programs to plan for scale rather than ration. The comparison point is lenacapavir, which took years of advocacy and pressure before pricing agreements brought it within reach for some low-income countries.
The underlying need is large. According to UNAIDS, 1.3 million people acquired HIV in 2023. Only 18 percent of the global PrEP need is currently being met, according to the Gates Foundation, which is co-funding the MK-8527 trials (Merck press release). The case for a once-monthly oral option is straightforward: daily pills require sustained adherence that many people cannot maintain, particularly in settings where stigma around HIV remains acute. A monthly pill removes some of that daily burden.
Merck has not announced a price for MK-8527 and Phase 3 results are not expected until the second half of 2027. The advocacy groups are making their argument now precisely because pricing decisions get locked in early — during regulatory review, during formulary negotiations, during the window when a company can shape what a drug means for global health before the price becomes a political fact. Merck's previous moves in this space are not without precedent. The company worked with the Gates Foundation on the HPV vaccine rollout and has had both wins and criticism on access. Where MK-8527 lands on that spectrum is an open question.
The Gates Foundation's Trevor Mundel, speaking at the IAS conference, put the stakes plainly: with only 18 percent of global PrEP need met, there is an urgent need for options that can be rolled out at scale. Whether Merck treats that as a commercial opportunity or a public health obligation — or some combination — is a decision that will be made before anyone outside a boardroom sees the Phase 3 data.
Story entered the newsroom
Assigned to reporter
Research completed — 13 sources registered. MK-8527 production cost estimated under $5/year vs. advocacy target of under $40/year. Narrowest pricing gap in any HIV prevention fight. 170 orgs fro
Draft (586 words)
Reporter revised draft (604 words)
Reporter revised draft (597 words)
Reporter revised draft (613 words)
Reporter revised draft (659 words)
Approved for publication
Published (596 words)
Get the best frontier systems analysis delivered weekly. No spam, no fluff.
Biotech & Life Sciences · 1h 26m ago · 3 min read
Biotech & Life Sciences · 1h 59m ago · 3 min read
